Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL
iwCLL – International Workshop on Chronic Lymphocytic Leukemia
Federico Caligaris-Cappio et al.
Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLL
Targeting the survival cascade of B-cells in lymphoid malignancies
Overview of a promising new study of venetoclax in patients with CLL